Evidence map›Paper›PMID 40568758›Full record

ArticleBiology open2025

CRISPR-Cas9 mediated RALA knockout and reconstitution: insights into the detection and role of RALA S194 phosphorylation in Ras-dependent and Ras-independent cancers.

Mayuresh Vishwas Konde, Siddhi Inchanalkar, Tushar Manik Sherkhane, Nilesh Deshpande, Mishika Virmani, Kajal Singh, Nagaraj Balasubramanian

Abstract read
In one paragraph

Article in Biology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mayuresh Vishwas KondeIISER Pune: Indian Institute of Science Education Research Pune, India.ORCID 0009-0009-6475-3347
Siddhi InchanalkarIISER Pune: Indian Institute of Science Education Research Pune, India.ORCID 0000-0001-6808-5096
Tushar Manik SherkhaneIISER Pune: Indian Institute of Science Education Research Pune, India.ORCID 0009-0008-5207-4614
Nilesh DeshpandeUniversity of Massachusetts Amherst, India.ORCID 0000-0002-3912-089X
Mishika VirmaniIISER Pune: Indian Institute of Science Education Research Pune, India.ORCID 0009-0003-5786-9989
Kajal SinghIISER Pune: Indian Institute of Science Education Research Pune, India.ORCID 0009-0004-7502-9032
Nagaraj BalasubramanianIISER Pune: Indian Institute of Science Education Research Pune, India.ORCID 0000-0002-8219-8844

Funding

IISER Pune: Indian Institute of Science Education Research Pune.Indian Council of Medical Research 35/03/2019-NANO/BMSIndian Council of Medical Research (ICMR) 35/03/2019-NANO/BMS
6 · The paper itself

Abstract

Downstream of oncogenic RAS, RALA is critical for cancer tumorigenesis, possibly regulated by phosphorylation of its Serine194 residue. We made CRISPR-Cas9 RALA knockout (RALA KO) in three RAS-dependent and two RAS-independent cancer cells. Detection of RALA S194 phosphorylation using the commercial anti-phospho-RALA antibody lacks specificity in all three RAS-dependent cancers. siRNA knockdown of RALA and AURKA inhibition by MLN8237 (VMLN) also did not affect pS194RALA detection in these cancers. RALA KO MiaPaCa2 (RAS-dependent) and MCF7 (RAS-independent) cells, stably reconstituted with WT-RALA and S194A-RALA mutants, showed no effect on RALA activation. Tumor growth was, however, restored partly by WT-RALA, but not S194A-RALA mutant. Thus, RALA S194 phosphorylation is needed for tumor formation, not affecting its activation, but possibly through its localization.

Indexed as

CRISPR-Cas SystemsNeoplasmsras ProteinsAnimalsCell Line, TumorGene Knockout TechniquesHumansPhosphorylationras ProteinsCRISPR-Cas9pS194RALARALARAS-dependentRAS-independentVMLN

Identifiers

PMID40568758
PMCPMC12320973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.